<!--
  Generated template for the GuidelinesPage page.

  See http://ionicframework.com/docs/components/#navigation for more info on
  Ionic pages and navigation.
-->
<ion-header>

    <ion-navbar color="footer">
        <button ion-button menuToggle>
            <ion-icon name="menu"></ion-icon>
        </button>
        <ion-title>Guidelines</ion-title>
    </ion-navbar>
    <ion-segment [(ngModel)]="segment" color="segment" (ionChange)="segmentChanged($event)">
        <ion-segment-button value="acute">
            Acute Bacterial
            <br> Rhinosinusitis
        </ion-segment-button>
        <ion-segment-button value="gas">
            GAS
            <br> Pharyngitis
        </ion-segment-button>
        <ion-segment-button value="community">
            Community Acquired
            <br> Pneumonia (CAP)
        </ion-segment-button>
    </ion-segment>
</ion-header>


<ion-content text-center>



    <div [ngSwitch]="segment">

        <div padding *ngSwitchCase="'acute'">
            <img src="assets/ref/g1.png" />
        </div>

        <div padding *ngSwitchCase="'gas'">
            <img src="assets/ref/g2.png" />
        </div>

        <ion-slides spaceBetween=50 pager=true padding *ngSwitchCase="'community'" direction="vertical">
            <ion-slide style="height: 700px">
                <img src="assets/ref/g3.jpg" />
                <ion-note style="float:right;font-size:xx-small">Adapted from ref. 3</ion-note>

            </ion-slide>
            <ion-slide>
                <p class="paragraph"> British thoracic society community acquired pneumonia in adults guidelines group october 2009 vol 64 supplement
                    III
                </p>
                <p class="paragraph2">Initial empirical treatment regimens for community acquired pneumonia (CAP) in adults </p>
                <table>
                    <thead>
                        <th WIDTH=31%>Pneumonia severity (based on clinical judgement supported by CURB65 severity score</th>
                        <th WIDTH=8.5% style="text-align:center">
                            Treatment site
                        </th>
                        <th WIDTH=30% style="text-align:center">
                            Preferred treatment
                        </th>
                        <th WIDTH=31%>
                            Alternative treatment
                        </th>

                    </thead>
                    <tbody>
                        <tr>
                            <td class="hover" (tap)="generatemodal('assets/ref/t1.png')">
                                <b>Low severity</b>
                                (eg, CURB65 = 0–1 or CRB65 score = 0,
                                <3% mortality) </td>
                                    <td>
                                        Home
                                    </td>
                                    <td>
                                        Amoxicillin 500 mg tds orally
                                    </td>
                                    <td>
                                        Doxycycline 200 mg loading dose then 100 mg orally or clarithromycin 500 mg bd orally
                                    </td>
                        </tr>
                        <tr>
                            <td class="hover" (tap)="generatemodal('assets/ref/t2.png')">
                                <b> Low severity </b>
                                (eg, CURB65 = 0–1,
                                <3% mortality) but admission indicated for reasons other than pneumonia severity (eg, social reasons/unstable comorbid illness)
                                    </td>
                                    <td>
                                        Hospital
                                    </td>
                                    <td>
                                        Amoxicillin 500 mg tds orally If oral administration not possible: amoxicillin 500 mg tds IV
                                    </td>
                                    <td>
                                        Doxycycline 200 mg loading dose then 100 mg od orally or clarithromycin 500 mg bd orally
                                    </td>
                        </tr>
                        <tr>
                            <td class="hover" (tap)="generatemodal('assets/ref/t3.png')">
                                <b> Moderate severity </b>
                                (eg, CURB65 = 2, 9% mortality)
                            </td>
                            <td>
                                Hospital
                            </td>
                            <td>
                                Amoxicillin 500 mg –1.0 g tds orally plus clarithromycin 500 mg bd orally If oral administration not possible: amoxicillin
                                500 mg tds IV or benzylpenicillin 1.2 g qds IV plus clarithromycin 500 mg bd IV
                            </td>
                            <td>
                                Doxycycline 200 mg loading dose then 100 mg orally or levofloxacin 500 mg od orally or moxifloxacin 400 mg od orally*
                            </td>
                        </tr>
                        <tr>
                            <td class="hover" (tap)="generatemodal('assets/ref/t4.png')">
                                <b> High severity </b>
                                (eg, CURB65 = 3–5, 15–40% mortality)
                            </td>
                            <td>
                                Hospital (consider critical care review)
                            </td>
                            <td>
                                Antibiotics given as soon as possible Co-amoxiclav 1.2 g tds IV plus clarithromycin 500 mg bd IV (If legionella strongly
                                suspected, consider adding levofloxacin†)
                            </td>
                            <td>
                                Benzylpenicillin 1.2 g qds IV plus either levofloxacin 500 mg bd IV or ciprofloxacin 400 mg bd IV OR Cefuroxime 1.5 g tds
                                IV or cefotaxime 1 g tds IV or ceftriaxone 2 g od IV, plus clarithromycin 500 mg bd IV (If
                                legionella strongly suspected, consider adding levofloxacin†)
                            </td>
                        </tr>
                    </tbody>
                </table>
                <p class="paragraph3">
                    bd, twice daily; IV, intravenous; od, once daily; qds, four times daily; tds, three times daily. *Following reports of an
                    increased risk of adverse hepatic reactions associated with oral moxifloxacin, in October 2008 the European
                    Medicines Agency (EMEA) recommended that moxifloxacin ‘‘should be used only when it is considered inappropriate
                    to use antibacterial agents that are commonly recommended for the initial treatment of this infection’’.
                    †Caution – risk of QT prolongation with macrolide-quinolone combination.
                </p>
                <ion-note style="float:right;font-size:xx-small"> Adapted from ref. 3 </ion-note>
            </ion-slide>
            <ion-slide>
                <img src="assets/ref/g32.png" />

            </ion-slide>
            <ion-slide>
                <p class="paragraph"> Empirical treatment of community acqiured pneumonia</p>
                <table align="center">
                    <colgroup span="2"></colgroup>
                    <colgroup span="2"></colgroup>
                    <tr>

                        <th class="rotate" WIDTH=2% rowspan="5">
                            <div>
                                <span>Outpatient treatment</span>
                            </div>
                        </th>
                        <th WIDTH=20% rowspan="2"> Type of patients, causative factor
                        </th>
                        <th style="text-align:center" WIDTH=50% colspan="2" scope="colgroup">First line treatment</th>
                        <th colspan="2" WIDTH=28% scope="colgroup">Second line treatment</th>
                    </tr>
                    <tr>
                        <th scope="col">Antibiotic</th>
                        <th scope="col">Dosage</th>
                        <th scope="col">Antibiotic</th>
                        <th scope="col">Dosage</th>
                    </tr>
                    <tr>
                        <td class="hover" (tap)="generatemodal('assets/ref/t5.png')" scope="row">Healthy individual and no antibiotics in previous 3 months </td>
                        <td>Clarithromycin (Biaxin Bid*) OR (Biaxin XL*) OR Azithromycin (Zithromax*)
                        </td>
                        <td>500 mg PO BID* 7 days 1000 mg PO BID* 7 days 500 mg PO on 1st day then 250 mg PO daily* 4 day
                        </td>
                        <td>Doxycyclin (Vibramycin*, Vibra-tabs*)</td>
                        <td>100 mg PO BID* 10 days
                        </td>
                    </tr>
                    <tr>
                        <td class="hover" (tap)="generatemodal('assets/ref/t6.png')" scope="row">
                            <b>Presence of comorbidities: </b> heart, pulmonary or renal disease, diabetes mellitus, alcoholism,
                            malignancy, immuno- suppression or use of antibiotics in previous 3 months
                        </td>
                        <td>Levofloxacin (Levaquin*) OR Moxifloxacin (Avelox*) OR Amoxicillin (High dose) Amoxicillin- clavulanate
                            potassium (Clavulin*) OR Cefuroxime axetil (Ceftin*) And Clarithromycin (Biaxin Bid*) OR (Biaxin
                            XL*) OR Azithromycin (Zithromax*)
                        </td>
                        <td>500 mg PO daily* 7−14 days OR 750 mg PO daily* 5 days 400 mg PO daily* 10 days OR 1000 mg PO TID*
                            10 days 875 mg PO BID or 500 mg PO TID* 10 days 500 mg PO BID* 7 days 500 mg PO BID* 7 days 1000
                            mg PO DIE* 7 days 500 mg PO on 1st day then 250 PO DIE* 4 days
                        </td>
                        <td></td>
                        <td></td>
                    </tr>
                    <tr>
                        <td class="hover" (tap)="generatemodal('assets/ref/t7.png')" scope="row">Patient residing in a long-term care facility (LTCF)

                        </td>
                        <td>Levofloxacin (Levaquin*) OR Moxifloxacin (Avelox*) OR Amoxicillin-clavulanate potassium (Clavulin*)
                            And Clarithromycin (Biaxin Bid*) OR (Biaxin XL*) OR Azithromycin (Zithromax*)
                        </td>
                        <td>500 mg PO daily* 7−14 days OR 750 mg PO daily* 5 days 400 mg PO daily* 10 days OR 875 mg PO BID or
                            500 mg PO TID* 10 days 500 mg PO BID* 7 days 1000 mg PO DIE* 7 days 500 mg PO on 1st day then
                            250 PO DIE* 4 days
                        </td>
                        <td></td>
                        <td></td>
                    </tr>
                    <tr>
                        <th class="rotate" id="blue" WIDTH=2%>
                            <div>
                                <span>Inpatient treatment</span>
                            </div>
                        </th>

                        <td class="hover" (tap)="generatemodal('assets/ref/t8.png')" scope="row">Hospitalized patient
                        </td>
                        <td>Levofloxacin (Levaquin*) OR Moxifloxacin (Avelox*) OR Cefotaxime (Claforan*) OR Ceftriaxone (Rocephin*)
                            And Clarithromycin (Biaxin Bid*) OR (Biaxin XL*) OR Azithromycin (Zithromax*)
                        </td>
                        <td>500 mg PO/IV DIE* 7−14 days OR 750 mg PO/IV* 5 days 400 mg PO/IV DIE* 7−14 days OR 1−2 g IV every
                            8 hours 1−2 g IV every 12−24 hours 500 mg PO BID* 7 days 1000 mg PO DIE* 7 days 500 mg IV every
                            24 hours
                        </td>
                        <td></td>
                        <td></td>
                    </tr>
                </table>
                <ion-note style="float:right;font-size:xx-small">Adapted from ref. 4</ion-note>
            </ion-slide>
            <ion-slide>
                <p class="paragraph"> Empirical treatment of community acqiured pneumonia</p>

                <table>

                    <tr>
                        <th class="rotate" id="blue" WIDTH=2%>
                            <div>
                                <span></span>
                            </div>
                        </th>

                        <td class="hover" (tap)="generatemodal('assets/ref/t9.png')" scope="row">Patient hospitalized in intensive care

                        </td>
                        <td>Levofloxacin (Levaquin*) OR Moxifloxacin (Avelox*)

                        </td>
                        <td>500 mg PO/IV DIE* 7−14 days OR 750 mg PO/IV* 5 days 400 mg PO/IV DIE* 7−14 days

                        </td>
                        <td>
                            Cefotaxime (Claforan*) OR Ceftriaxone (Rocephin*) AND Clarithromycin (Biaxin Bid*) OR (Biaxin XL* ) OR Azithromycin (Zithromax*)

                        </td>
                        <td>
                            1-2 g IV every 8 hours 1-2 g IV every 12-24 hours 500 mg PO BID* 7 days 1000 mg PO DIE* 7 days 500 mg IV every 24 hour


                        </td>
                    </tr>
                </table>

                <ion-note style="float:right;font-size:x-small">Adapted from ref. 4</ion-note>
                <p class="paragraph3">
                    *adapted from IDSA and ATS consensus guidelines on the management of community acquired pneumonia in adults. clinical infectious
                    disease 2007, 44( suppl) †one of main risk factors for S. pneumonia resistance is the use of antibiotics
                    in the previous 3 months. in which case a different class of antibiotic should be selected ‡The antibiotics
                    are listed in alphabetical order of their genetic name. only one brand name product is listed although
                    several manufacturers may market other brand names. §View macrolides under treatment guidelines #when
                    administering respiratory quinolones, the interval recommended between the use of quinolones and the
                    use of medication containing bivalent or trivalent loss (Iron, Calcium, Aluminium, Magnesium, Multivitamin,
                    Minerals)
                </p>
            </ion-slide>

        </ion-slides>

    </div>

</ion-content>
<ion-footer no-lines>
    <img (click)="gotofooter()" src="assets/ref/{{segment_footer}}" />
</ion-footer>